Ashvarya Mangla, MD
Interventional Cardiology · Chicago, ILNPI 1457580680
Payments from drug & device makers
Across 99 payments — averaging $360.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Abbott$15K
- Edwards Lifesciences$1K
- GE HealthCare$273
- Boston Scientific$157
- W. L. Gore & Associates, Inc.$141
- plus $604 from 10 others
What the payments were for
- Grants$27,09076%
- Travel & lodging$3,82111%
- Food & beverage$4,78013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 3 | $18,089 |
| Abbott | 51 | $15,404 |
| Edwards Lifesciences | 18 | $1,024 |
| GE HealthCare | 3 | $273 |
| Boston Scientific | 3 | $157 |
| W. L. Gore & Associates, Inc. | 1 | $141 |
| Impulse Dynamics (USA) Inc. | 1 | $131 |
| Cardiovascular Systems Inc. | 7 | $116 |
| Biosense Webster, Inc. | 1 | $83 |
| Getinge USA Sales, LLC | 4 | $76 |
| Cardiva Medical, Inc. | 2 | $52 |
| Shockwave Medical, Inc | 1 | $51 |
| Abiomed | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Terumo Medical Corporation | 1 | $20 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,691 in reported general payments places this provider in the 75th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $211,613 |
| EntrestoSacubitril/Valsartan | 154 | $173,185 |
| JardianceEmpagliflozin | 54 | $47,951 |
| XareltoRivaroxaban | 34 | $39,815 |
| BrilintaTicagrelor | 38 | $38,101 |
| Praluent PenAlirocumab | 26 | $15,808 |
| Repatha SureclickEvolocumab | 17 | $9,551 |
| Metoprolol Succinate | 288 | $3,889 |
| Ranolazine ErRanolazine | 25 | $3,851 |
| Atorvastatin Calcium | 405 | $3,548 |
| Rosuvastatin Calcium | 147 | $2,222 |
| ClopidogrelClopidogrel Bisulfate | 169 | $1,840 |
| Carvedilol | 248 | $1,688 |
| Bumetanide | 26 | $1,307 |
| Isosorbide Dinitrate | 16 | $1,131 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Chicago
- Charles DavidsonChicago$5.8M
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Hussam SuradiChicago$455K
- Fareed Moses ColladoChicago$278K
- Keith BenzulyChicago$271K
- David StewartChicago$241K
- Sandeep KhoslaChicago$228K
- Daniel SchimmelChicago$221K
- Ranya SweisChicago$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.